BioCentury
ARTICLE | Deals

First newco from BMS-BioMotiv deal launches to target fibrosis, inflammation

February 4, 2020 10:25 PM UTC

Five months after forming a build-to-buy partnership, BMS and pharmaceutical accelerator BioMotiv have launched their first company. Anteros Pharmaceuticals will develop small molecules to treat fibrotic and inflammatory diseases.

As part of the partners' September build-to-buy agreement to form and fund companies across multiple disease areas, Bristol-Myers Squibb Co. (NYSE:BMY) became an LP of BioMotiv LLC. ...